Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is Changing

Frank Vinluan / medcitynews - Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a deal that taps into Chinese labs to source biotech innovation. This alliance will focus on developing next-generation drugs in the c…

AI Summary: Pfizer struck a $10.5 billion deal to acquire a leading Chinese oncology biotech, a transaction industry watchers say underlines China’s accelerating drug‑development muscle. Analysts flagged broader implications for global R&D competition, partnerships and where future oncology innovation — and manufacturing heft — might live.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Novartis pays $2B for Synnovation’s next‑gen PI3Kα inhibitor / 2 months

Gilead acquires Tubulis in multibillion-dollar push beyond HIV / 7 wks

Merck to acquire Terns Therapeutics for $6.7B / 2 months

Eli Lilly acquires CrossBridge Bio in oncology deal up to $300M / 6 wks

UCB acquires Candid for $2B to pursue T‑cell engager therapies / 22 days

Chiesi acquires KalVista for $1.9B to bolster rare disease pipeline / 29 days

TerraPower invests $450M to build Actinium‑225 radioisotope factory / 2 months